New pill takes on bile duct cancer: phase 3 trial launches
Disease control
Not yet recruiting
This Phase 3 trial tests a new daily pill, TT-00420, against standard chemotherapy in 138 adults with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or mutation) and has worsened after first treatment. The study compares how long the cancer stays under…
Phase: PHASE3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC